While limited in scope, a new meta-analysis of patient outcomes reveals that compounded hormones provide real benefits to patients and also find that compounded hormones pose no increased risk compared to FDA-approved products.
As part of its commission, NASEM was to review the body of patient-outcome studies for compounded hormones. NASEM chose to ignore that data, instead selecting only 13 studies to include in its report, mostly featuring hormones that are not among the most commonly prescribed. (Studies that matched their predetermined outcome?)
This report, published in Menopause, the journal of the North American Menopause Society, is exactly the kind of unbiased research that NASEM should have done but didn't.
To better understand the threat to compounded hormone therapy, watch this video briefing from a
compounding pharmacist, prescriber of compounded medications, and a compounding policy expert.
Congress has oversight of the FDA. We need to make our voices heard in Congress before the FDA takes ill-conceived action that deprives millions of people of the critical therapy they need to live normally. We need you to join this cause; together we need to fight to protect compounded hormones.
This meta-study, published by the journal Menopause, is the scientific research that NASEM should have done, but failed to do. Yes, more studies of patient outcomes are vital, but this important study contrasts sharply with claims in the NASEM report.
If the FDA uses its (demonstrably) flawed NASEM study to put compounded hormones on the "Demonstrably Difficult to Compound" list, it will deny thousands of people in your state access to a vital medical therapy. Hormones have been compounded for decades, and patient-outcomes research shows that they provide lasting benefits to patients.
Understand this important issue before it profoundly impacts people's lives.
Is CBHT a vital therapy? Ask a physician.
The loss of compounded hormones as a treatment option for hormonal imbalance is a major health issue that will significantly affect physicians’ and pharmacists’ ability to treat their patients. It will deny physicians a critical option for patients who, for whatever reason, cannot take FDA-approved drugs.
Hear from one group of physicians, in their own words.
It excluded the insights of both physicians and pharmacists with extensive, patient-facing experience.
When the FDA signaled that it might severely restrict access to compounded hormones, we launched a campaign to raise awareness among patients, doctors and, especially, members of Congress.
When you contribute to this campaign — you are protecting access to this life-changing therapy for millions of patients.